L-Isoleucine As Immunotherapeutic Supplement For Effective In Vivo Expression Of Human Beta Defensins To Combat Covid-19 Evidenced By Insilico Protein-Protein Interactions

Abstract

COVID-19 is a deadly and highly infectious disease and at present is prevalent all over the world. As there is no fixed medicine available at present for covid-19, researchers all over the world are trying different medicines available already to take over this deadly virus. In this regard, we suggest L-Isoleucine as immunotherapeutic drug supplement to enhance the expression of human beta defensins protein. Defensins are the antiviral proteins present in human body as a component of innate immunity. Research studies revealed that L-Isoleucine enhance the production of beta defensins in pneumonia induced mice and known to decrease pneumonia pathogenesis significantly. Interestingly, beta defensins also suppress the inflammation mediated by macrophages. Novel corona virus utilizes the spike protein interaction with ACE2 receptor as entry portal in to host cells. Molecular docking revealed that negative binding energy between β defensin and virus spike protein was greater than negative binding energy between virus spike protein and ACE2 receptor. Hence, L-Isoleucine may be suggested to humans for increasing innate antiviral β defensins and prevent the novel coronavirus entry in to lung epithelial cells.